Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1328-1334

  Wang, Yang ^a   Wei, Yudan ^b   Zhang, Haiying ^a   Shi, Yanfen ^a   Li, Yulin ^a   Li, Ronggui ^a  

^a JILIN UNIVERSITY   (China)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Catalase; Osteosarcoma; ROS

Indexed keywords

ACETYLCYSTEINE; ARSENIC TRIOXIDE; CATALASE; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MESSENGER RNA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; GLUTATHIONE; ORGANOARSENIC DERIVATIVE; OXIDE; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BONE TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; BONE NEOPLASMS; CATALASE; CELL LINE, TUMOR; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; OSTEOSARCOMA; OXIDES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866306093     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9848-5     Document Type: Article

References (32)

1. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78-87.
2. Overholtzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA. 2003;100: 11547-52.
3. Ueda Y, Dockhorn-Dworniczak B, Blasius S, et al. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol. 1993;119:172-8.
4. Goto A, Kanda H, Ishikawa Y, et al. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res. 1998;89:539-47.
5. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered. Blood Rev. 2010;24:191-9.
6. Yedjou C, Tchounwou P, Jenkins J, McMurray R. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol. 2010;3:28-36.
7. Lafayette TC, Coser VM, Brule AO, et al. External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature. J Pediatr Hematol Oncol. 2010;32:229-32.
8. Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004;93:173-87.
9. Mann KK, Wallner B, Lossos IS, Miller WH Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs. 2009;18:1727-34.
10. Li Y, Qu X, Qu J, et al. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3 K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009;284: 208-15.
11. Yoda A, Toyoshima K, Watanabe Y, et al. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem. 2008;283:18969-79.
12. Fei M, Lu M, Wang Y, et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol. 2009;26:178-85.
13. Akay C, Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle. 2003;2:358-68.
14. Kircelli F, Akay C, Gazitt Y. Arsenic trioxide induces p53- dependent apoptotic signals in myeloma cells with SiRNAsilenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53. Int J Oncol. 2007;30:993-1001.
15. Wu X, Shi J, Wu Y, et al. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther. 2011;10:1201-14.
16. Shi Y, Wei Y, Qu S, et al. Arsenic induces apoptosis of human umbilical vein endothelial cells through mitochondrial pathways. Cardiovasc Toxicol. 2010;10:153-60.
17. Engel RH, Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci. 2006;11:300-12.
18. Liu SX, Athar M, Lippai I, et al. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci USA. 2001;98:1643-8.
19. Wang LW, Shi YL, Wang N, et al. Association of oxidative stress with realgar-induced differentiation in human leukemia HL-60 cells. Chemotherapy. 2009;55:460-7.
20. Sumi D, Shinkai Y, Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol Appl Pharmacol. 2010;244:385-92.
21. Yedjou CG, Moore P, Tchounwou PB. Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment. Int J Environ Res Public Health. 2006;3:136-40.
22. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Leuk Lymphoma. 2000;38:283-93.
23. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422-41.
24. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007; 19:341-6.
25. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009;45:2367-75.
26. Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol. 2005;37:2478-503.
27. Bartz RR, Piantadosi CA. Clin ical review: oxygen as a signaling molecule. Crit Care. 2010;14:234.
28. Sanchez Y, Calle C, de Blas E, Aller P. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases. Chem Biol Interact. 2009;182: 37-44.
29. Das J, Ghosh J, Manna P, et al. Taurine protects rat testes against NaAsO(2)-induced oxidative stress and apoptosis via mitochondrial dependent and independent pathways. Toxicol Lett. 2009;187:201-10.
30. Han YH, Kim SZ, Kim SH, Park WH. Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine. Mol Cells. 2008;26:18-25.
31. Wang W, Adachi M, Kawamura R, et al. Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis. 2006;11:2225-35.
32. Islam KN, Kayanoki Y, Kaneto H, et al. TGF-beta1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic Biol Med. 1997;22:1007-17.